SK bioscience to speed up Ebola virus vaccine development with CEPI funding

SK bioscience, a biopharmaceutical arm of Korea's SK Group, said Thursday it will accelerate the development of a Zaire Ebola virus vaccine with funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The announcement follows a funding agreement between CEPI and U.S. pharmaceutical company MSD to support continued development of the vaccine. Under the agreement, CEPI will provide $30 million to MSD, which will allocate the funds to its development partners, including SK bioscience and Hilleman Laboratories, the company said in a press release. "Addressing deadly infectious diseases, such as Ebola, requires strong global collaboration," SK bioscience Chief Executive Officer (CEO) Ahn Jae-yong said. "Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving Zaire Ebola virus vaccine manufacturing and supply, contributing to global health preparedness." Hilleman Laboratories is a joint venture between MSD and Wellcome, a global charitable foundation focused on health research. Hilleman will lead clinical development of an updatWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times